Affiliation:
1. Odesa National Medical University, Ukraine
Abstract
The objective: to analyze the effectiveness of prevention of reflux-related complications in patients with chronic calculous prostatitis and prostatic hyperplasia after surgical removal of prostatic hyperplasia and stones.
Materials and methods. The study included patients 56–70 years old with prostatic hyperplasia and stones. They were divided into two groups. The first group included 28 patients who underwent a retrospective study of reflux pyelonephritis and epididymitis after surgical removal of hyperplastic tissues and stones of the prostate gland without the use of pathogenetically justified prophylaxis. The second group included 26 patients who underwent a study of reflux pyelonephritis and epididymoorchitis after surgical removal of hyperplastic tissues and stones of the prostate gland with the use of pathogenetic justified drug therapy.
The patients underwent objective, laboratory, bacteriological and biochemical research, ultrasound examination of the prostate gland and bladder. Blood flow in the prostate gland was studied by Doppler.
Results. In 14.2 % of patients in the first group, who received traditional medical treatment in the postoperative period, acute reflux pyelonephritis developed, in 17.8 % – epididymitis. Patients of the second group were prescribed one of the alpha1-adrenoceptor blockers and suppositories with a non-steroidal drug in the postoperative period together with traditional medical therapy. In patients of the second group, acute reflux pyelonephritis was not determined after surgical treatment, and epididymitis developed in 1 (3.3 %) of 26 persons.
Conclusions. It has been determined that the prescription of alpha1-adrenoceptor blocker is an effective method of preventing of reflux-related pyelonephritis and epididymitis development in the patients in the early postoperative period after surgical removal of hyperplastic tissues and stones of the prostate gland in order to eliminate spastic obstruction, as well as prescription of non-steroidal drug to reduce the inflammatory process and edema in the prostate and bladder neck.
Subject
General Earth and Planetary Sciences,Water Science and Technology,Geography, Planning and Development
Reference29 articles.
1. Evidence for a mechanistic association between nonbacterial prostatitis and levels of urate and creatinine in expressed prostatic secretion.;Persson;J Urol,1996
2. Uhal OM, inventor. Odesa State Medical University, patent holder. A method of modeling chronic prostatitis. Patent No. 47121. 2010 Jan 11. Ukraine.
3. Peculiarities of morphogenesis of experimental reflux-induced chronic prostatitis;Ukhal;Health of Man,2010
4. PREDICTORS OF PATIENT RESPONSE TO ANTIBIOTIC THERAPY FOR THE CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME: A PROSPECTIVE MULTICENTER CLINICAL TRIAL;NICKEL;Journal of Urology,2001
5. Naber KG. Chronic (Bacterial) Prostatitis. Complicated Urinary Tract Infections: Lectures in Hospital Infections. London; 2003, p. 13–31.